Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TNAX Biopharma

Request full access

A developer of pharmaceutical drugs intended to improve the quality of life of patients

Tokyo, JapanFounded 2018Biotech & Life Sciences

About TNAX Biopharma

TNAX Biopharma Corporation, established in March 2018, is a privately held biopharmaceutical firm specializing in the discovery and development of novel antibody therapeutics. The company was co-founded by CEO Tak Mukohira and Chief Scientific Officer Dr. Akira Shibuya. Mr. Mukohira brings over 35 years of experience in business development and corporate strategy from his time at pharmaceutical companies like Mitsubishi Tanabe Pharma, including serving as President of its Boston-based venture capital arm. His background is complemented by Dr. Shibuya, a renowned immunologist and professor at the University of Tsukuba, who had 12 years of clinical experience before his research career. TNAX Biopharma was officially authorized as a startup originating from the University of Tsukuba, with which it conducts joint research and leverages exclusively licensed intellectual property.

The company's core focus is on developing pharmaceuticals that target the interaction between immunoreceptors and their ligands to treat intractable diseases with unmet medical needs. Its business model revolves around drug discovery innovation and forming strategic alliances for further development and commercialization. A key partnership is an exclusive worldwide licensing agreement with IMIDomics Inc., granting them the rights to develop and commercialize TNAX101A (renamed IMB1001). This agreement includes upfront payments, milestone achievements, and royalties, demonstrating a clear revenue generation strategy through licensing and collaboration.

TNAX Biopharma's pipeline addresses critical conditions such as acute kidney injury (AKI), acute ischemic stroke (AIS), and other immune-mediated inflammatory diseases. One of its leading candidates, TNAX103, is a humanized anti-CD300a monoclonal antibody designed to inhibit ischemia-reperfusion injury (IRI). This antibody functions as an efferocytosis promoter, enhancing the clearance of dead cells to suppress inflammation and prevent further tissue damage, which is a major trigger in conditions like cardiac surgery-associated AKI and stroke. Another key asset is IMB1001, a humanized antibody targeting CD226, which has shown potential to treat immune-mediated inflammatory diseases like ulcerative colitis by downregulating pro-inflammatory cytokines and exhibiting anti-fibrotic activity.

Source: Dealroom company data

TNAX Biopharma in the Tokyo ecosystem

Live from Dealroom

The TNAX Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • JAFCO

Series A2 investors entered at this stage

  • Mitsubishi UFJ Capital
  • Nissay Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇯🇵 Japan · Tokyo HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TNAX Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TNAX Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.